

Cancer Drug Development Forum

ANNUAL CONFERENCE

How can we accelerate cancer drug development and access for EU patients ?

8 - 10 February 2027
Antwerp, BE
Hybrid Conference

www.cddf.org

EVENT OUTLINE

Coming soon.

LEARNING OBJECTIVES

Coming soon.

PROGRAM COMMITTE

- Committee chair: Mark Lawler (CDDF, UK)
- Co-chairs: Fergus Sweeney (CDDF, IE); Rosa Giuliani (CDDF, IT)
- Birgit Wolf (Bayer, DE)
- Richard Vart (Eli Lilly, UK)
- Andrew Evans (WECAN, NL)

TARGET AUDIENCE

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), pharmaceutical Industry, HTAs and patient advocates.

CONFERENCE VENUE

Van Der Valk Hotel Park Lane Antwerp (Van Eycklei 34, 2018 Antwerp, Belgium)

HYBRID CONFERENCE

The conference will be held in Antwerp. However, participation online via the Brella event platform will also be possible. Only approved participants will receive the link and log-in details to access the virtual platform.

CONTACT

Cancer Drug Development Forum (CDDF)
Email: shannon@cddf.org, info@cddf.org
Website: www.cddf.org
Address: c/o BLSI Clos Chapelle-aux-Champs 30, 1200 Brussels, Belgium

PROGRAM

Day 1 : Monday, 8 February 2027

SESSION 1: THE EVOLVING LANDSCAPE FOR CANCER MEDICINES

Session Chairs: Mark Lawler (CDDF, UK); Richard Vart (Eli Lilly, UK)

12:00 - 13:00	Welcome Lunch
13:00 - 13:05	Welcome note Mark Lawler (CDDF, UK)
13:05 - 13:20	Key Note Lecture from Academia
13:20 - 13:35	Key Note Lecture Scott Greenfeder (Bayer, US)
13:35 - 13:50	Key Note from European Commission Edit Szepessy (European Commission, BE)
13:50- 14:30	Panel Discussion
14:30 - 15:00	Coffee Break

SESSION 2: MAKING EUROPE A PREMIER LOCATION TO RUN CANCER TRIALS

Session Chairs: Mark Lawler (CDDF, UK); Ruth Plummer (CDDF, UK)

15:00 - 15:10	Setting the scene
15:10 - 15:25	Industry perspective Noha Kassem (Eli Lilly, UK)
15:25 - 15:40	ACT EU Catherine Paugam-Burtz (ANSM, FR)

15:40 - 15:55	Patient perspective
15:55 - 16:10	Academic perspective Mark Lawler (CDDF, UK)
16:10 - 17:00	Panel Discussion
17:30 - 18:30	CDDF Leadership and Industry Members meeting (internal meeting)
19:00 - 22:00	Offsite dinner at Fidèle

Day 2 : Tuesday, 9 February 2027

SESSION 3: NEXT-GENERATION EVIDENCE GENERATION AND TRIAL DESIGN

Session Chairs: Fergus Sweeney (CDDF, IE); Jana Pelouchova (CDDF, CZ)

08:00 - 09:45	CDDF Board Meeting (internal meeting)
10:10 - 10:15	Session opening
10:15 - 10:30	Accelerating access without compromising evidence: perspectives on oncology development Caroline Pothet (EMA, NL)
10:30 - 10:45	Innovative Trial Design
10:45 - 11:00	Diversity Project
11:00 - 11:50	Panel Discussion
12:00 - 14:00	Offsite lunch at Fiera

SESSION 4: EXPEDITED PATHWAYS IN THE GLOBAL CONTEXT

Session Chairs: Rosa Giuliani (CDDF, IT), Birgit Wolf (Bayer, DE)

14:00 - 14:05	Session opening
14:05 - 14:15	Setting the scene
14:15 - 14:30	Regulatory perspective
14:30 - 14:45	Industry perspective Els Caenen (Johnson & Johnson, BE)
14:45 - 15:00	FDA Perspective Jeevan Puthiamadathil (FDA, US)
15:00 - 15:50	Panel Discussion
16:00 - 17:30	World Café
19:00 - 22:00	Onsite dinner

Day 3 : Wednesday, 10 February 2027

SESSION 5: TRANSLATING EXPEDITED DEVELOPMENT AND AUTHORIZATION INTO ACCESS AND AVAILABILITY

Session Chairs: Rosa Giuliani (CDDF, IT); TBC

10:00 - 10:05	Session opening
10:05 - 10:20	Setting the scene
10:20 - 10:35	EU HTA Coordination group
10:35- 10:50	Industry perspective
10:50 - 11:05	Case Study
11:05 - 11:55	Panel Discussion

SESSION 6: CONFERENCE WRAP-UP AND NEXT STEPS

Session Chairs: Mark Lawler (CDDF, UK); Fergus Sweeney (CDDF, IE)

11:55 - 12:15	Wrap up panel discussion
12:15 - 12:20	Farewell message Mark Lawler (CDDF, UK)
12:20- 13:20	Lunch and departure